Furthermore, the co-existence of doxorubicin and PI3K/AKT pathway inhibitor abolished the doxorubicin-induced nuclear up-regulation of PD-L1, suggesting the significant role of the PI3K/AKT pathway in the nuclear upregulation of PD-L1 in BC cells [172,173]. This evidence concerns the gene AKT1 and breast cancer.